Figure 1 from Effect on Hemoglobin A1c (HbA1c) and Body Weight After ...

FIGURE 1 : Change in HbA1c from the start of study drug administration to week 52 - " Effect on Hemoglobin A1c ( HbA1c ) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist: A Single-Center Case Series Study"

Fifty-two weeks after randomization, study drug administration was discontinued. To investigate progress after the end of administration, changes in hemoglobin A1c ( HbA1c ) and body weight were further examined two, four, and six months after discontinuation of the study drug.
Effect on Hemoglobin A1c (HbA1c) and Body Weight After ...

Long-acting GLP-1 RAs (liraglutide, once-weekly exenatide, dulaglutide, albiglutide, and semaglutide) have more profound effects on overnight and fasting plasma glucose and HbA1c , both on a ...
To investigate progress after the end of administration, changes in hemoglobin A1c ( HbA1c ) and body weight were further examined two, four, and six months after discontinuation of the study drug. Results After fifty-two weeks, all tirzepatide groups had improved HbA1c and body weight compared with the dulaglutide group.

Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation ...
After fifty-two weeks, all tirzepatide groups had improved HbA1c and body weight compared with the dulaglutide group. At two, four, and six months after the end of study drug administration, re-elevation of HbA1c was observed in all groups.
The duration of the off-drug treatment period was 4 weeks, which is not enough to affect HbA1c and body weight fully or determine the long-term effects of discontinuing tirzepatide treatment.

Overview of Figure 1 From Effect On Hemoglobin A1C Hba1C And Body Weight After
Introduction To evaluate real-world hemoglobin A1c ( HbA1c ) and weight change in adults initiating treatment with tirzepatide (dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist [GLP-1 RA]) or injectable semaglutide (GLP-1 RA) indicated for type 2 diabetes (T2D) management. Methods This retrospective analysis utilized the Healthcare Integrated ...
This post hoc analysis assessed the HbA1c -lowering efficacy of semaglutide, a GLP-1RA, in participants with a range of kidney functions in the SUSTAIN 4-6 and 10 (subcutaneous semaglutide) and PIONEER 5 and 6 (oral semaglutide) clinical trials. Trial-level changes from baseline to end of treatment (EOT) in HbA1c and body weight (BW) were assessed in participants with estimated glomerular ...

Key Details About Figure 1 From Effect On Hemoglobin A1C Hba1C And Body Weight After
TZP was more efficacious than placebo or SEMA in reducing HbA1c and BW across a spectrum of pancreatic beta-cell function, notably achieving greater glycemic improvement in people with markers of diminished pancreatic beta cell function at baseline.




Figure 3 shows changes in HbA1c over the course of the trial and two years after drug discontinuation. Two months after discontinuing tirzepatide, re-elevation of HbA1c was observed ( Figure 3). ...